Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Preclinical Characterization of PRT7732: A Highly Potent, Selective, and Orally Bioavailable Targeted Protein Degrader of SMARCA2

Tuesday, April 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the preclinical characterization of PRT7732, a targeted protein degrader of SMARCA2. Researchers highlight its high potency, selectivity, and oral bioavailability, suggesting its potential as a therapeutic agent. The findings indicate promising avenues for further development in targeted therapies.
Price reaction · baseline $4.91 (2024-04-16 close) · hit after-hours · 1 other PRLD headline(s) in the window, move may be shared
day 0 close
-14.9%
day 1 · peak
-29.9%
day 3
-21.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT7732 shows high potency and selectivity.
  • The compound is orally bioavailable, enhancing its usability.
  • Targeted protein degradation may offer new therapeutic avenues.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Artem Shvartsbart , Koichi Ito , Joseph Rager, Liang Lu, Michael Hulse, Anjana Agarwal, Komali Vykuntam, Jessica Burtell, Min Wang, Justin Kurian, Miles Cowart, Joy Cote, Nick Stahl, Monisha Sivakumar, Anthony Reichelderfer, Jack Carter, Alex Grego, Carly Bachner, Andrew Moore, Neha Bhagwat, Ross Kuskovsky, Shanthi Ganesan, Stefan Ruepp, Tom Emm, Philip Pitis, Corey Basch, Klare Bersch, Yongchun Pan, Song Mei, Raul Leal, John Rose, Danielle Roth, Chaoyi Xu, Karl Blom, Ganfeng Cao, Kris Vaddi, Sang Hyun Lee, Sandy Geeganage, Andrew Combs, Peggy Scherle

Frequently Asked Questions

What is PRT7732?

PRT7732 is a highly potent and selective targeted protein degrader of SMARCA2.

What are the benefits of PRT7732?

PRT7732 offers high potency, selectivity, and is orally bioavailable.

What does SMARCA2 target in therapy?

SMARCA2 is a protein that PRT7732 aims to degrade for therapeutic effects.

What stage is PRT7732 in development?

PRT7732 is currently in the preclinical stage of development.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT7732 SMARCA2 targeted therapy protein degradation preclinical studies
Last updated: Apr 16, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →